Based: Mountain View, CA
Investors: HBM BioVentures, Undisclosed Firm, Odlander, Fredrikson, OrbiMed Advisors, Alta Partners, Undisclosed Firm
Scoop: ChemoCentryx dropped an IPO in 2008 but was able to raise $50 million in funding. The company is developing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx's most advanced program is Traficet-EN, which is in Phase III trials for Crohn's disease, Phase II for Celiac disease and Phase I for ulcerative colitis. Additionally, the company is in Phase I trials for several other drug candidates: CCX025 for gastrointestinal diseases, CCX140 for vascular restenosis and multiple sclerosis, and CCX 354 for rheumatoid arthritis.